Literature DB >> 21264920

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.

Hui Yang, Zhihong Fang, Yue Wei, Yumin Hu, George A Calin, Hagop M Kantarjian, Guillermo Garcia-Manero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21264920      PMCID： PMC3652683          DOI： 10.1002/ajh.21937

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

2.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Authors:  Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'brien; Elihu Estey; Carlos Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2007-06-27       Impact factor: 22.113

4.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

Authors:  Ramiro Garzon; Shujun Liu; Muller Fabbri; Zhongfa Liu; Catherine E A Heaphy; Elisa Callegari; Sebastian Schwind; Jiuxia Pang; Jianhua Yu; Natarajan Muthusamy; Violaine Havelange; Stefano Volinia; William Blum; Laura J Rush; Danilo Perrotti; Michael Andreeff; Clara D Bloomfield; John C Byrd; Kenneth Chan; Lai-Chu Wu; Carlo M Croce; Guido Marcucci
Journal:  Blood       Date:  2009-02-11       Impact factor: 22.113

5.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

Review 6.  MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.

Authors:  M Fabbri; R Garzon; M Andreeff; H M Kantarjian; G Garcia-Manero; G A Calin
Journal:  Leukemia       Date:  2008-03-06       Impact factor: 11.528
  6 in total
  4 in total

Review 1.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism.

Authors:  Anuradha Kalani; Pradip K Kamat; Anastasia Familtseva; Pankaj Chaturvedi; Nino Muradashvili; Nithya Narayanan; Suresh C Tyagi; Neetu Tyagi
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-07       Impact factor: 6.200

3.  Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.

Authors:  A Mims; A R Walker; X Huang; J Sun; H Wang; R Santhanam; A M Dorrance; C Walker; P Hoellerbauer; S S Tarighat; K K Chan; R B Klisovic; D Perrotti; M A Caligiuri; J C Byrd; C-S Chen; L James Lee; S Jacob; K Mrózek; C D Bloomfield; W Blum; R Garzon; S Schwind; G Marcucci
Journal:  Leukemia       Date:  2012-11-26       Impact factor: 11.528

4.  Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663.

Authors:  Pan Jian; Zhao Wen Li; Tao Yan Fang; Wang Jian; Zhou Zhuan; Liao Xin Mei; Wu Shui Yan; Ni Jian
Journal:  J Hematol Oncol       Date:  2011-04-25       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.